A number of reports have illustrated that while the BCR-Abl fusion protein is the initiating molecule for CML, there is a crucial down-stream role for Lyn in BCR-Abl induced leukemogenesis [82,83]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.